|
CN102796705A
|
|
Dac hyp compositions and methods
|
|
WO2011084496A1
|
|
Anti-her2 antibodies and their uses
|
|
EP2470901A1
|
|
Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
|
|
CN102753580A
|
|
Anti-egfr antibodies and their uses
|
|
AU2010286427A1
|
|
Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
|
|
BRPI0918842A2
|
|
method for treating multiple sclerosis patients with anti-il2r antibodies
|
|
US2009136950A1
|
|
Immunoglobulin display vectors
|
|
EP2425849A2
|
|
Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
|
|
HK1099699A1
|
|
Therapeutic use of anti-cs1 antibodies
|
|
CN1933851A
|
|
Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
|
|
EP1708961A2
|
|
Anti-ip-10 antibodies
|
|
US2008063646A1
|
|
Treatment of inflammatory bowel diseases with anti-IP-10 antibodies
|
|
KR20110140143A
|
|
CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS
|
